Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$470 Mln
Revenue (TTM)
$248 Mln
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
130.9
P/B Ratio
2.4
Industry P/E
54.26
EV/EBITDA
12
Div. Yield
0.8 %
Debt to Equity
1.1
Book Value
$--
EPS
$0.6
Face value
--
Shares outstanding
5,524,813
CFO
$234.05 Mln
EBITDA
$179.34 Mln
Net Profit
$52.88 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mesa Laboratories (MLAB)
| 16.0 | -5.7 | 16.0 | -22.5 | -19.5 | -18.2 | -0.7 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Mesa Laboratories (MLAB)
| -40.5 | 25.6 | -37.0 | -49.3 | 14.5 | 14.9 | 19.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mesa Laboratories (MLAB)
|
91.1 | 470.0 | 247.5 | 3.7 | 6.9 | 2.1 | 130.9 | 2.4 |
| 7.9 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 25.8 | 3,989.0 | 2,719.5 | 47.0 | 8.4 | 1.6 | 86.6 | 1.3 | |
| 112.8 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control... segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado. Address: 12100 West Sixth Avenue, Lakewood, CO, United States, 80228 Read more
CEO, President & Director
Mr. Gary M. Owens
CEO, President & Director
Mr. Gary M. Owens
Headquarters
Lakewood, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Mesa Laboratories Inc (MLAB) is $91.08 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Mesa Laboratories Inc (MLAB) has given a return of -19.52% in the last 3 years.
The P/E ratio of Mesa Laboratories Inc (MLAB) is 130.88 times as on 31-Mar-2026, a 141 premium to its peers’ median range of 54.26 times.
The P/B ratio of Mesa Laboratories Inc (MLAB) is 2.37 times as on 31-Mar-2026, a 20 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-326.35
|
4.03
|
|
2024
|
-2.33
|
4.07
|
|
2023
|
1,010.99
|
2.39
|
|
2022
|
715.60
|
3.40
|
|
2021
|
394.33
|
3.18
|
The 52-week high and low of Mesa Laboratories Inc (MLAB) are Rs 129.61 and Rs 55.45 as of 03-Apr-2026.
Mesa Laboratories Inc (MLAB) has a market capitalisation of $ 470 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Mesa Laboratories Inc (MLAB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$2.62
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.